Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data
Secukinumab, a selective interleukin (IL)-17A inhibitor, is approved for use in adult and paediatric psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis. The aim of this study was to report the long-term safety of secukinumab in pooled data from 28 cli...
Saved in:
Main Authors: | Alice B. Gottlieb (Author), Atul Deodhar (Author), Iain B. Mcinnes (Author), Xenofon Baraliakos (Author), Kristian Reich (Author), Stefan Schreiber (Author), Weibin Bao (Author), Kwaku Marfo (Author), Hanno B. Richards (Author), Luminita Pricop (Author), Abhijit Shete (Author), Vivek Trivedi (Author), Deborah Keefe (Author), Charis C. Papavassilis (Author), Piotr Jagiello (Author), Philemon Papanastasiou (Author), Philip J. Mease (Author), Mark Lebwohl (Author) |
---|---|
Format: | Book |
Published: |
Medical Journals Sweden,
2022-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials
by: Rui Sun, et al.
Published: (2024) -
Secukinumab Associated Choroidal Neovascularization
by: Edward B Miller, et al.
Published: (2022) -
Secukinumab
by: Nilgün Atakan
Published: (2022) -
Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence
by: Jashin J. Wu, et al.
Published: (2020) -
T cell epitope mapping of secukinumab and ixekizumab in healthy donors
by: Sebastian Spindeldreher, et al.
Published: (2020)